Schwab Charles Investment Management Inc. Purchases 189,438 Shares of Opko Health, Inc. (OPK)
Schwab Charles Investment Management Inc. boosted its position in Opko Health, Inc. (NASDAQ:OPK) by 20.9% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,095,177 shares of the biotechnology company’s stock after purchasing an additional 189,438 shares during the quarter. Schwab Charles Investment Management Inc. owned about 0.20% of Opko Health worth $7,207,000 at the end of the most recent quarter.
Other large investors have also recently modified their holdings of the company. Public Employees Retirement Association of Colorado increased its stake in Opko Health by 0.3% during the 2nd quarter. Public Employees Retirement Association of Colorado now owns 73,417 shares of the biotechnology company’s stock valued at $483,000 after buying an additional 216 shares during the period. Envestnet Asset Management Inc. increased its stake in Opko Health by 6.5% during the 1st quarter. Envestnet Asset Management Inc. now owns 16,356 shares of the biotechnology company’s stock valued at $132,000 after buying an additional 1,001 shares during the period. Van ECK Associates Corp increased its stake in Opko Health by 1.5% during the 1st quarter. Van ECK Associates Corp now owns 83,984 shares of the biotechnology company’s stock valued at $672,000 after buying an additional 1,274 shares during the period. Essex Investment Management Co. LLC increased its stake in Opko Health by 0.8% during the 2nd quarter. Essex Investment Management Co. LLC now owns 266,949 shares of the biotechnology company’s stock valued at $1,757,000 after buying an additional 2,153 shares during the period. Finally, Janney Montgomery Scott LLC increased its stake in Opko Health by 10.8% during the 2nd quarter. Janney Montgomery Scott LLC now owns 28,579 shares of the biotechnology company’s stock valued at $188,000 after buying an additional 2,787 shares during the period. Hedge funds and other institutional investors own 22.46% of the company’s stock.
Opko Health, Inc. (NASDAQ:OPK) opened at 7.00 on Friday. The firm’s market cap is $3.92 billion. Opko Health, Inc. has a 52 week low of $5.85 and a 52 week high of $12.15. The stock has a 50 day moving average of $6.44 and a 200 day moving average of $6.75.
Opko Health (NASDAQ:OPK) last announced its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.04) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.05) by $0.01. The firm had revenue of $314.20 million during the quarter, compared to analysts’ expectations of $322.64 million. Opko Health had a negative return on equity of 3.67% and a negative net margin of 6.52%. The company’s quarterly revenue was down 12.0% compared to the same quarter last year. During the same period in the previous year, the business posted $0.02 EPS. Analysts anticipate that Opko Health, Inc. will post ($0.19) EPS for the current year.
Several research firms have commented on OPK. BidaskClub raised shares of Opko Health from a “strong sell” rating to a “sell” rating in a research note on Thursday, June 22nd. Ladenburg Thalmann Financial Services reissued a “buy” rating and set a $16.00 target price on shares of Opko Health in a research note on Monday, September 25th. J P Morgan Chase & Co cut shares of Opko Health from an “overweight” rating to a “neutral” rating and lowered their target price for the company from $12.00 to $7.00 in a research note on Thursday, September 14th. Jefferies Group LLC reissued a “hold” rating and set a $6.50 target price (down previously from $6.80) on shares of Opko Health in a research note on Thursday, August 10th. Finally, Zacks Investment Research raised shares of Opko Health from a “hold” rating to a “buy” rating and set a $7.25 target price on the stock in a research note on Friday, July 21st. Five research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $13.97.
In related news, CEO Phillip Md Et Al Frost purchased 12,600 shares of the stock in a transaction dated Friday, July 14th. The stock was bought at an average cost of $6.16 per share, with a total value of $77,616.00. Following the purchase, the chief executive officer now directly owns 3,068,951 shares in the company, valued at approximately $18,904,738.16. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last ninety days, insiders bought 992,000 shares of company stock valued at $6,077,053. 40.19% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/schwab-charles-investment-management-inc-purchases-189438-shares-of-opko-health-inc-opk/1616724.html.
Opko Health Profile
OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.
Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.